PL2560611T3 - Sposób wytwarzania cząstek o zredukowanych ładunkach eIektrostatycznych - Google Patents

Sposób wytwarzania cząstek o zredukowanych ładunkach eIektrostatycznych

Info

Publication number
PL2560611T3
PL2560611T3 PL11719211T PL11719211T PL2560611T3 PL 2560611 T3 PL2560611 T3 PL 2560611T3 PL 11719211 T PL11719211 T PL 11719211T PL 11719211 T PL11719211 T PL 11719211T PL 2560611 T3 PL2560611 T3 PL 2560611T3
Authority
PL
Poland
Prior art keywords
electrostatic charges
providing particles
reduced electrostatic
reduced
particles
Prior art date
Application number
PL11719211T
Other languages
English (en)
Inventor
Daniela Cocconi
Rossella Musa
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42710544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2560611(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL2560611T3 publication Critical patent/PL2560611T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
PL11719211T 2010-04-21 2011-04-19 Sposób wytwarzania cząstek o zredukowanych ładunkach eIektrostatycznych PL2560611T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10160565 2010-04-21
EP11719211.2A EP2560611B1 (en) 2010-04-21 2011-04-19 "process for providing particles with reduced electrostatic charges"
PCT/EP2011/056227 WO2011131663A1 (en) 2010-04-21 2011-04-19 "process for providing particles with reduced electrostatic charges"

Publications (1)

Publication Number Publication Date
PL2560611T3 true PL2560611T3 (pl) 2018-05-30

Family

ID=42710544

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11719211T PL2560611T3 (pl) 2010-04-21 2011-04-19 Sposób wytwarzania cząstek o zredukowanych ładunkach eIektrostatycznych

Country Status (26)

Country Link
US (3) US20110262543A1 (pl)
EP (1) EP2560611B1 (pl)
JP (1) JP5913289B2 (pl)
KR (2) KR20130062268A (pl)
CN (1) CN102858320B (pl)
AR (1) AR081540A1 (pl)
AU (1) AU2011244384B2 (pl)
BR (1) BR112012026804B1 (pl)
CA (1) CA2796934C (pl)
DK (1) DK2560611T3 (pl)
ES (1) ES2658179T3 (pl)
HR (1) HRP20180488T1 (pl)
HU (1) HUE038555T2 (pl)
IL (1) IL222519B (pl)
MX (1) MX2012012045A (pl)
MY (1) MY163011A (pl)
NO (1) NO2560611T3 (pl)
PH (1) PH12012501988B1 (pl)
PL (1) PL2560611T3 (pl)
PT (1) PT2560611T (pl)
RU (1) RU2580312C2 (pl)
SG (1) SG184964A1 (pl)
SI (1) SI2560611T1 (pl)
TW (1) TWI530301B (pl)
UA (1) UA111470C2 (pl)
WO (1) WO2011131663A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013142268A (ru) * 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
DE102011102614A1 (de) * 2011-05-27 2012-11-29 Roland Nied Verfahren zum Betrieb einer Strahlmühle sowie Strahlmühle
EP2804583A1 (en) * 2012-01-16 2014-11-26 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
WO2013109208A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations comprising formoterol as active agent
WO2013109209A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising fluticasone
DK3527199T3 (da) 2012-01-25 2022-10-24 Chiesi Farm Spa Tørpulverformulering omfattende et kortikosteroid og et beta-adrenergikum til indgivelse via inhalation
GB201205632D0 (en) * 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
BR112014025518B1 (pt) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
WO2014106727A1 (en) * 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
KR102275904B1 (ko) 2013-07-11 2021-07-13 키에시 파르마슈티시 엣스. 피. 에이. 흡입에 의한 투여를 위한 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201700536XA (en) 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
PT3689379T (pt) 2015-11-16 2021-09-24 Chiesi Farm Spa Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticoide e um betaadrenérgico
CN105891616B (zh) * 2016-06-15 2018-06-15 北京航空航天大学 一种研究带电颗粒与火焰相互作用的实验装置
WO2018018669A1 (en) * 2016-07-28 2018-02-01 Esd Technology Consulting & Licensing Co., Ltd. Static charge reduction system
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
EP3833964B1 (en) 2018-08-07 2023-07-26 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
KR102898819B1 (ko) 2019-09-24 2025-12-12 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말 제제를 위한 신규 담체 입자
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
US20240033222A1 (en) 2020-08-14 2024-02-01 Norton (Waterford) Limited An inhalable formulation of fluticasone propionate and albuterol sulfate
CN116077471A (zh) * 2021-11-08 2023-05-09 上海臣邦医药科技股份有限公司 一种供吸入用的粉雾剂组合物及其制备方法和应用
US20250050042A1 (en) 2021-12-21 2025-02-13 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
CN115400103B (zh) * 2022-09-22 2023-11-24 苏州易合医药有限公司 一种多孔性呼吸颗粒及其制备方法
CA3268243A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
CN115770221A (zh) * 2022-12-29 2023-03-10 浙江上药九旭药业有限公司 银杏酮酯粉体、银杏酮酯滴丸剂及其制备方法
WO2026027448A1 (en) 2024-07-29 2026-02-05 Inke, S.A. Micronization process of indacaterol acetate

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
CZ295460B6 (cs) * 1997-03-20 2005-08-17 Schering Corporation Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující
CA2347856C (en) * 1998-11-13 2009-02-17 Jagotec Ag Dry powder for inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
CA2413692C (en) * 2000-06-27 2011-10-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
JP2009513529A (ja) * 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
HUE058227T2 (hu) 2004-04-23 2022-07-28 Cydex Pharmaceuticals Inc DPI készítmény, amely szulfoalkil-éter-ciklodextrint tartalmaz
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
EP2044023B1 (en) 2006-07-14 2011-01-19 CHIESI FARMACEUTICI S.p.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof

Also Published As

Publication number Publication date
EP2560611A1 (en) 2013-02-27
IL222519A0 (en) 2012-12-31
JP2013525327A (ja) 2013-06-20
EP2560611B1 (en) 2018-01-03
AU2011244384B2 (en) 2016-06-23
TW201206498A (en) 2012-02-16
MX2012012045A (es) 2012-12-17
NO2560611T3 (pl) 2018-06-02
MY163011A (en) 2017-07-31
TWI530301B (zh) 2016-04-21
CA2796934A1 (en) 2011-10-27
RU2580312C2 (ru) 2016-04-10
AU2011244384A1 (en) 2012-11-15
HRP20180488T1 (hr) 2018-07-13
AR081540A1 (es) 2012-10-03
ES2658179T3 (es) 2018-03-08
US20110262543A1 (en) 2011-10-27
KR20170118975A (ko) 2017-10-25
IL222519B (en) 2018-03-29
SG184964A1 (en) 2012-11-29
UA111470C2 (uk) 2016-05-10
CN102858320A (zh) 2013-01-02
CN102858320B (zh) 2014-10-29
DK2560611T3 (en) 2018-02-26
BR112012026804B1 (pt) 2021-11-16
PH12012501988B1 (en) 2018-03-07
US20230364015A1 (en) 2023-11-16
PH12012501988A1 (en) 2013-04-14
HUE038555T2 (hu) 2018-10-29
US20190216731A1 (en) 2019-07-18
JP5913289B2 (ja) 2016-04-27
SI2560611T1 (en) 2018-03-30
WO2011131663A1 (en) 2011-10-27
PT2560611T (pt) 2018-02-07
BR112012026804A2 (pt) 2016-07-12
RU2012145762A (ru) 2014-05-27
HK1174570A1 (en) 2013-06-14
KR20130062268A (ko) 2013-06-12
KR101863523B1 (ko) 2018-05-31
CA2796934C (en) 2018-11-20

Similar Documents

Publication Publication Date Title
PT2560611T (pt) Processo para proporcionar partículas com cargas eletrostáticas reduzidas
KR101429591B9 (ko) 정전 척
EP2603926A4 (en) DETECTOR FOR LOADED PARTICLES
GB2472098B (en) An electrostatic filter
GB2492660B (en) Particle separator
ZA201304696B (en) Anti-cd38 antibodies
EP2607960A4 (en) LOAD ELEMENT
IL213724A0 (en) Coated powder particles
GB201109319D0 (en) Fine particles
SG10201505888TA (en) Particle size breakup apparatus
EP2699670A4 (en) PARTICLES SYNTHETIZED FROM CELLS
PL2380962T3 (pl) Cząstka
ZA201208013B (en) " selp-standing comtainer "
GB0903134D0 (en) Charged particle motion inducing apparatus
ZA201303361B (en) Process for extrusing particles
GB201002038D0 (en) Electrostatic capacitors
EP2546698A4 (en) TONER FOR DEVELOPMENT WITH ELECTROSTATIC CHARGE
GB201012693D0 (en) An electrostatic precipitator
AU2010900937A0 (en) Particle precipitator
HK1180637A (zh) 颗粒沉淀器
GB201014944D0 (en) "An improved atomiser"
GB201113678D0 (en) "Data-Tank"
GB201013564D0 (en) Bloomin' bin cover
AU2011903847A0 (en) Functional Particles
EP2515173A4 (en) TONER FOR ELECTROSTATIC USE